FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i>-Mutated Metastatic Castrate-Resistant Prostate CancerMitchell S. Anscher, Julia A. Beaver, Xin Gao et al.|The Oncologist|2020Cited by 74